Cogent Biosciences, Inc.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsCogent Biosciences is a clinical-stage biotechnology company developing bezuclastinib, a KIT inhibitor for systemic mastocytosis and gastrointestinal stromal tumors, with three NDAs pending FDA review and a planned US launch in H2 2026.
What they do
Cogent Biosciences is a clinical-stage biotechnology company developing precision therapies for genetically defined diseases. Its lead program, bezuclastinib (CGT9486), is a selective tyrosine kinase inhibitor targeting KIT D816V and other exon 17 mutations, being developed for NonAdvSM, AdvSM, and GIST. The company also has early-stage programs including an FGFR2/3 inhibitor, a CNS-penetrant mutant ErbB2 inhibitor, and preclinical PI3K, KRAS, and JAK2 programs.
Revenue drivers
- Bezuclastinib in NonAdvSM — Expected commercial launch in the US in H2 2026 pending FDA approval; estimated global market opportunity of approximately $3.5 billion for NonAdvSM.
- Bezuclastinib in AdvSM — NDA submitted June 2026; estimated global market opportunity of approximately $500 million for AdvSM.
- Bezuclastinib in GIST (combination with sunitinib) — NDA accepted with priority review; estimated global market opportunity of over $4 billion as a second-line treatment for GIST.
Recent performance
Cogent Biosciences reported no product revenue; as of June 30, 2026, total assets were $834.5 million and cash & equivalents were $181.2 million. Net losses have widened from $72.3 million in 2021 to $328.9 million in 2025, with operating cash flow of -$264.4 million in 2025. In Q2 2026, the company reported a pro forma cash balance of $865.9 million, including proceeds from debt and equity. The company has not generated any revenue from product sales.
Strategy
Cogent is focused on advancing bezuclastinib through regulatory approval and launching it commercially in the US in H2 2026. The company is building an internal commercial organization, having completed onboarding of field-based commercial and medical teams. It plans to evaluate collaborations and licensing opportunities, and continues to invest in early-stage pipeline programs including FGFR2/3, ErbB2, PI3K, KRAS, and JAK2. Management expects to use its cash balance to fund operations into late 2028.
Risks
- Regulatory approval risk — NDAs for bezuclastinib are pending FDA review and may not be approved, or approval may be delayed, impacting the planned H2 2026 launch.
- Commercial execution risk — Cogent has no commercial experience and must build a sales organization and compete with established players in oncology and rare disease markets.
- Dependence on single product — The company is highly dependent on bezuclastinib; failure in any indication would materially harm its business.
- Financial sustainability risk — The company has a history of net losses and negative operating cash flow, and may need additional funding to support operations beyond late 2028.
Outlook
Management expects FDA decisions for bezuclastinib in GIST (PDUFA November 30, 2026) and NonAdvSM (PDUFA December 30, 2026), with an AdvSM NDA already submitted. The company projects a US launch in H2 2026, building a commercial team and leveraging a pro forma cash balance of $865.9 million to fund operations into late 2028. Management also continues to invest in pipeline programs and explore partnerships.